• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: ROCHE MOLECULAR SYSTEMS, INC. - BRANCHBURG COBAS® LIAT® SARS-COV-2 & INFLUENZA A/B; COVID-19 MULTI-ANALYTE RESPIRATORY PANEL NUCLEIC ACID DEVICES

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

ROCHE MOLECULAR SYSTEMS, INC. - BRANCHBURG COBAS® LIAT® SARS-COV-2 & INFLUENZA A/B; COVID-19 MULTI-ANALYTE RESPIRATORY PANEL NUCLEIC ACID DEVICES Back to Search Results
Catalog Number 09211101190
Device Problems Incorrect, Inadequate or Imprecise Result or Readings (1535); Output Problem (3005); Non Reproducible Results (4029)
Patient Problem No Clinical Signs, Symptoms or Conditions (4582)
Event Date 11/25/2021
Event Type  malfunction  
Manufacturer Narrative
A customer from australia alleged discrepant results while using the cobas® sars-cov-2 & influenza a/b nucleic acid test for use on the cobas® liat® system.An investigation was performed to evaluate the customer issue.Data was provided and reviewed and it was seen that run #810 produced a positive result for the sars target with a delayed ct of 36.42.The curve was representative of low level amplification in the limit of detection (lod) range.The data indicated the sample contains a viral target concentration at the limit of detection for the assay, so discrepancies at this level can be expected with repeat testing.It is possible one or multiple of the samples pooled had low-level virus present and therefore lod results were generated upon testing.The issue is sample specific and no product problem was identified.No analyzer issue was seen in the provided data set.Additionally, the practice of testing pooled samples with this test is considered off-label and not recommended.Per the ifu, "this test is intended to be used for the detection of sars-cov-2, influenza a and influenza b rna in nasal and nasopharyngeal swab samples collected in a copan utm-rt system (utm-rt) or bd¿ universal viral transport system (uvt) or thermo fisher¿ scientific remel¿ media, or thomas scientific mantacc¿ premeasured 3 ml 0.9% physiological saline solution.Testing of other sample or media types may lead to inaccurate results." it is unknown how testing pooled samples may affect results.The issue is sample specific and no product problem was identified.(b)(4).
 
Event Description
In light of the covid-19 pandemic and the subsequent emergency use authorizations (euas) for sars-cov-2 diagnostic tests, the agency has requested heightened reporting beyond the reasonably suggests requirements of 803 to include allegations of false positive or false negative results independent of harm or malfunction or off-label use.Pursuant to the agency¿s instruction, we hereby submit this mdr.The customer alleged discrepant results generated for the cobas® sars-cov-2 & influenza a/b (scfa) assay.A customer from australia alleged that they received a potential false positive result for a patient¿s sample tested with the cobas® sars-cov-2 & influenza a/b (scfa) assay.The customer reported that run # 810 produced a sars-cov-2 positive result from a pooled test, analyzed on the cobas® liat® system (s/n (b)(4)).The customer separated the pool, the individual samples from the pool produced a sars-cov-2 negative result analyzed on the cobas® liat® system (s/n (b)(4)).The pooled samples from run # 810 was repeat tested and analyzed on a different cobas® liat® system (s/n not provided) that generated a sars-cov-2 negative result.No patient details were made available, and no harm or injury was indicated.No information on sample collection or handling was provided.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
COBAS® LIAT® SARS-COV-2 & INFLUENZA A/B
Type of Device
COVID-19 MULTI-ANALYTE RESPIRATORY PANEL NUCLEIC ACID DEVICES
Manufacturer (Section D)
ROCHE MOLECULAR SYSTEMS, INC. - BRANCHBURG
1080 us highway 202 south
branchburg NJ 08876
Manufacturer (Section G)
ROCHE MOLECULAR SYSTEMS, INC. - BRANCHBURG
1080 us highway 202 south
na
branchburg NJ 08876
Manufacturer Contact
stacie-ann creighton
1080 us hwy 202 s
na
branchburg, NJ 08876
9082537112
MDR Report Key13081825
MDR Text Key290561527
Report Number2243471-2021-03893
Device Sequence Number1
Product Code QLT
Combination Product (y/n)N
Reporter Country CodeAS
PMA/PMN Number
EUA201779
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type Foreign,Health Professional
Reporter Occupation Other Health Care Professional
Type of Report Initial
Report Date 12/23/2021
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? No
Is this a Product Problem Report? Yes
Device Operator Health Professional
Device Expiration Date05/31/2022
Device Catalogue Number09211101190
Device Lot Number10628X
Is the Reporter a Health Professional? Yes
Initial Date Manufacturer Received 11/25/2021
Initial Date FDA Received12/23/2021
Was Device Evaluated by Manufacturer? Device Not Returned to Manufacturer
Is the Device Single Use? Yes
Is This a Reprocessed and Reused Single-Use Device? Yes
Patient Sequence Number1
-
-